#REMSWITCH IV->SQ IFX No⬆️ #IBD relapse if IV 5-10mg/kg q6-8wks ↪️120mg SQ eow ⬆️Relapse if 🔺IV 10mg/kg q4wks 🔺Baseline IFX TL>11 🔺Baseline FCP>250 🔺No⬆️IFX TL post-↪️ ⚠️These pts need 240mg SQ eow ⚠️Higher IFX TL needed w SQ for 🟰efficacy CGH doi.org/10.1016/j.cgh.…

SEQUENCE phase 3b RCT Clear evidence of superiority for risankizumab over ustekinumab in Crohn’s disease Endoscopic remission at week 48 double with RZB (31.8%) vs UST (16.2%) Hugely important data - for more results including study design keep reading👇

Risankizumab vs ustekinumab SEQUENCE study #UEGWeek

Mesenchymal stem cells for perianal Crohn's disease? Looks like they don't work after all "Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint

🌞🌞 Very pleasant memories of MilestoneIBD retreat in Scottsdale. The ‘official’ group picture is now out 👇🏻👇🏿👇🏽 See you all soon 🌞🌞 Christina Ha MD Carrie Bristor Mohammad Alomari, MD Idan Goren Manar Askar @KristiCBriggs Tarun Chhibba @akmd03 Jalpa Devi Joseph Sleiman, MD, FACP

Cardiovascular & VTE Risk With JAKi in Immune-Mediated Inflammatory Skin Diseases 🔎35 RCT: >20k patients ✅No difference JAKi vs placebo/active comparator in composite MACE &all-cause mortality (OR, 0.83; 95% CI, 0.44-1.57) or VTE (OR, 0.52; 0.26-1.04) jamanetwork.com/journals/jamad…

#AHN23 AHN Gastroenterology, Hepatology and Nutrition Proctitis symptoms (urgency, tenesmus…) can really affect UC pt QOL Gursimran Kochhar MD #Etrasimod shows efficacy in isolated #proctitis 👇🏽 💭 Can It also be an option as an add-on in pts with pan-UC in remission on a biologic except for that stubborn rectum ?

Excellent overview of JAK inhibitors by Edward Loftus #AIBD2023 ✅Highly effective even in bio-exposed ✅Rapid onset, many seeing response within 2 weeks ✅MACE risk likely negligible in pts <65, w/o CV risk factors, who are not smokers ❌ avoid use in smokers

Nayantara Coelho on management of dysplasia in IBD #AIBD ✅ random biopsies most helpful in PSC ✅ make the invisible (lesions) visible w/ dye spray chromo ✅ endoscopic management (EMR, ESD) of dysplasia when possible ✅ tailor surveillance interval to patient

Diagnostic Performance of a Fecal Calprotectin Assay as a Biomarker for Mayo Endoscopic Subscore in Ulcerative Colitis pubmed.ncbi.nlm.nih.gov/38309716/ IBDJournal & CC360 Tanita Suttichaimongkol David Bruining Raseen Tariq, MD, MS

I'm honored and excited to have our abstract get accepted at #DDW2024 meeting. All thanks to my mentor Amanda Johnson, MD for her unparalleled guidance and support! Mayo Clinic Gastroenterology & Hepatology Digestive Disease Week #GITwitter

Extensive Ulcerative Colitis and Exposure to Multiple Biologics precolectomy is associated with Endoscopic Cuffitis in IPAA patients. #IBD Crohn's & Colitis Foundation Mayo Clinic Gastroenterology & Hepatology

Induction and post-induction serum vedolizumab were not consistently associated with biochemical normalization. Proactive TDM for vedolizumab should not be routinely incorporated in a treat to target strategy for IBD Cynthia Seow John K. Marshall MD Journal of the Canadian Assn of Gastroenterology academic.oup.com/jcag/advance-a…

Antibiotic 💊 use in 12 months prior to IPAA, ⬆️ risk of Pouchitis. #ibd #crohns #colitits

The #REBOOTIBD group (minus a few) with our poster on RWE of risankizumab in Crohns Manar Askar Parakkal Deepak MD, MS, FACG Ryan Ungaro MD MS Shrinivas Bishu Andres Yarur Richa Shukla Jalpa Devi

🎊 Congratulations to our 2024 Class of Graduating Fellows! 🎊 Whatever is next in your journey, we wish you all the best! Graduation was held at #mayowoodstonebarn on June 4th

Congratulations 🎊🎉🎈🍾 to Priscila Santiago, MD and #ManarAskar on completing #IBD fellowship and looking forward to Siri Urquhart, M.D. and Katie Dunleavy starting!!! Thank you Victor Chedid, MD and Amanda Johnson, MD for coming!

Colorectal neoplasia surveillance intervals in IBD. - high-definition white light colonoscopy ✅ - good bowel preparation✅

New research - D’Haens et al - Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial thelancet.com/journals/langa… #GITwitter #IBD

🚨AGA New Guideline Alert🚨 🔗gastrojournal.org/article/S0016-… ▶️AGA Living Guideline: Pharmacological Management of Moderate-Severe Ulcerative Colitis I’ll break down its 14 recommendations down over the next 7 tweets 🧵 👇 #AGA #GI #UC #IBD #MedTwitter 1/9